To perform a mutation screening of TACSTD2 in 13 Iranian Gelatinous Drop-like Corneal Dystrophy (GDLD) pedigrees. To assess genotype-phenotype correlations. To determine intragenic SNP haplotypes associated with the mutations, so as to gain information on their origin. METHODS. The coding region of TACSTD2 was sequenced in the probands of 13 unrelated Iranian GDLD pedigrees. Variations were assessed in other available affected and unaffected family members and in unrelated normal control subjects by restriction fragment length polymorphism (RFLP). The variations were classified as being associated with disease if they segregated with the disease phenotype in the families, were not observed in 100 control individuals, disrupted protein expression, or affected conserved positions in the coded protein.
G elatinous drop-like corneal dystrophy (GDLD, corneal familial subepithelial amyloidosis; OMIM 204870; Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/ Omim/ provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD) is a rare inherited disease first described by Nakaizumi in 1914. 1 It is characterized by the deposition of amyloid material in the subepithelial space of the cornea. GDLD is one of several forms of corneal dystrophies which are accompanied by amyloidosis, the others being Avellino corneal dystrophy (ACD) and different types of lattice corneal dystrophy (LCD). Clinical symptoms of GDLD most often manifest within the first decade of life. Nodular depositions in the central cornea which appear in the early stage of disease later increase in number and depth and coalesce, usually to create a protruding whitish-yellow mulberry appearance. [2] [3] [4] Other forms of coalescence have also been reported. 5 Neovascularization of the subepithelial and superficial stroma may appear in advanced stages of the disease. 6 Affected individuals experience lacrimation, photophobia, foreign body sensation, and blurred vision. Eventually, gelatinous masses severely impair visual acuity and penetrating or lamellar keratoplasty, photoablation, or keratectomy is prescribed. Unfortunately, symptoms generally recur within a few years after intervention, and repeated keratoplasties are often performed. 7 GDLD is inherited in an autosomal recessive fashion. 8, 9 The disease has most often been reported in the Japanese population, in which its incidence is estimated at 1 in 300,000. 8 A locus on the short arm of chromosome 1 was linked to the disease by homozygosity mapping of patients of this population in 1998. 6 Later, Membrane component, chromosome 1, Surface marker 1 (M1S1), originally identified as the gene encoding gastrointestinal tumor-associated antigen and also known as GA733-1 and TROP2, was identified as the causative gene at this locus. 10 The official name of the gene is now TACSTD2 (tumor associated calcium signal transducer 2). 11 A founder mutation, Q118X, was found in this gene among Japanese patients with GDLD. 8 In addition to Japan, cases of GDLD from India, [12] [13] [14] Tunisia, 3, [13] [14] [15] and other countries 13,14,16 -21 have also been reported. Putative disease-causing mutations in TACSTD2 were found in almost all cases in which mutation screening of the gene was performed. 10,14,18 -28 In total, 19 different GDLD-causing alterations in TACSTD2 have been reported to date. 10,14,18 -21,25,26 However, three unrelated GDLD pedigrees have been identified wherein mutations in TACSTD2 were not found, suggesting genetic heterogeneity for the disease. 14, 28, 29 The previously reported GDLD-causing mutations in TACSTD2 are presented in Table 1 .
The TACSTD2 gene product is a multimodule transmembrane glycoprotein of 323 amino acids. The domains of the protein include an epidermal growth factor (EFG)-like repeat, a thyroglobulin type 1A (TY) repeat, a transmembrane domain (TM), and a phosphatidylinositol (PIP2)-binding site. 10 It has been suggested that the coded protein functions as a cell-cell adhesion receptor in cancer cells and as a calcium signal transducer. 30, 31 With respect to GDLD, it FIGURE 1. Geographic origin of Iranian GDLD patients. The geographic origins of the patients are shown with dots (F) within the provinces. The numbers indicate the TACSTD2 sequence variations associated with disease: 1, C66X; 2, F114C; 3, L186P; 4, E227K. has been shown that the corneal epithelium of affected eyes has notably increased permeability, and it has been suggested that this may be a direct consequence of the abnormal TACSTD2 protein expressed in the tissue. 32, 33 The increased permeability is likely to be relevant to the pathogenesis of the disease. Among Middle Eastern countries, one GDLD pedigree from Turkey has been described. 21 Herein, we report the results of mutation screening of TACSTD2 in 13 Iranian GDLD pedigrees. Four putative disease-causing mutations in TACSTD2, three of which are novel, were identified in the 13 pedigrees. An intragenic SNP haplotype associated with a common Iranian TACSTD2 mutation is presented, and the possibility of its being a founder mutation is considered.
MATERIALS AND METHODS
This research was performed in accordance with the Declaration of Helsinki and with the approval of the ethics board of the International Institute of Genetic Engineering and Biotechnology in Iran. Thirteen Iranian GDLD pedigrees were identified. All families consented to participate after being informed of the nature of the research. In total, 41 individuals belonging to these families were studied: 13 probands (one from each family), 8 additional affected individuals, and 20 unaffected individuals. The probands were first diagnosed with GDLD in the years between 1987 and 2005. Diagnosis was made by corneal specialists at the Farabi Hospital (associated with Tehran University of Medical Sciences) and the Labbafi-Nejhad Hospital (associated with Shaheed Beheshti University of Medical Sciences and Health Services) in Tehran. The hospitals are national reference centers, and patients from throughout the country are referred to them. Diagnosis of GDLD was based on classic clinical appearance and slit-lamp biomicroscopy. Individuals whose corneal surfaces had a mulberry-like appearance were considered to be affected. The diagnosis in all but two cases (probands of pedigrees 100-3 and 100-6) was confirmed with histopathology by staining for amyloid with congo red. Ocular, medical, and family histories were obtained for each available family member. Nine of the probands were offspring of consanguineous marriages. Both parents in the four remaining pedigrees came from small isolated villages wherein blood relationships between individuals are highly likely. One hundred ethnically matched unrelated healthy control individuals without a family history of eye diseases (self reported) were also recruited for the study.
The single exon of TACSTD2 was amplified from the DNA of the 13 probands. Amplification was usually performed by two polymerase chain reactions (PCR) with primers M1S1-Fa (5Ј-GAGTATAAGAGCCG-GAGGGAG-3Ј) and M1S1-Ra (5Ј-CATCGCCGATATCCACGTCAC-3Ј), and M1S1-Fb (5Ј-CTGAGCCTACGCTGCGATGAG-3Ј) and M1S1-Rb (5Ј-GGATCTATTAAACCTGGTGTGTG-3Ј). There was a 244-nucleotide overlap in the two amplified products. Together, they provided the sequence of the entire 972-nucleotide coding region, and 109 nucleotides upstream, and 139 nucleotides downstream of the coding region. Amplification was sometimes performed in a single reaction with primers M1S1-Fa and M1S1-Rb. PCR with primers M1S1-Fa and M1S1-Ra and PCR with primers M1S1-Fa and M1S1-Rb were performed with a touchdown protocol.
The amplified products were sequenced in both forward and reverse directions with the PCR primers using dye termination chemistry (Big Dye kit and the Prism 3700 squencer; Applied Biosystems [ABI], Foster City, CA). Sequences were analyzed on com- Five of the sequence variations found in TACSTD2 were assessed in available affected and nonaffected family members by restriction enzyme digestion and fragment length polymorphism (RFLP). They were also assessed in the 100 unrelated control individuals by the same procedure. Variations found in more than 1% of the chromosomes of our control cohort were considered polymorphisms. Core haplotypes defined by two intragenic polymorphisms and one rare variation in TACSTD2 were assessed in the probands and control individuals using PLINK (provided in the public domain by the Psychiatric and Neurodevelopmental Genetics Unit, Harvard Medical School, Boston, MA, at http://pngu.mgh.harvard.edu/ϳpurcell/plink).
RESULTS
Ten of the 13 Iranian GDLD pedigrees were from northern Iran and three came from provinces in central Iran (Fig. 1) . The clinical features of the probands are presented in Table 2 . Typical slit lamp photographs and histologic sections of the corneas of patients are presented in Figure 2 . Diagnosis of GDLD was based on clinical and histologic features such as those evident in this figure.
Seven sequence variations were identified in the TACSTD2 gene of the Iranian patients with GDLD (Table 3) . They were all observed in the homozygous state. Five of the variations resulted in amino acid changes, one created a stop codon, and one was in the 5Ј noncoding region. c.198CϾA causing C66X was found in one patient and is a novel variation. It was assessed to be associated with GDLD, as it creates a stop codon early in the coding region, within the EGF-like domain. The protein product of the mutated allele is expected to be the shortest truncated TACSTD2 reported to date. Previously, mutation K84X, coding a slightly longer truncated product, was reported as one of two disease-causing mutations in TACSTD2 in a Japanese patient with GDLD 25 c.341TϾG causing F114C, c.557TϾC causing L186P, and c.679GϾA causing E227K were also associated with disease. L186P found in one Iranian patient has been described as a disease-causing mutation in a Japanese patient. 26 This mutation produces an amino acid change at a conserved position in the region between the TY and TM domains of the protein, wherein several disease-asso- (Table 4 and Ref. 14) . F114C observed in one Iranian patient, has not been previously reported. The only sibling of the proband, who was also affected, was unavailable, but the nucleotide change which caused the amino acid substitution was not observed in the DNA of 100 control individuals. F114C causes the nonconservative substitution of a polar for a nonpolar amino acid within the TY domain of TACSTD2. Phenylalanine at position 114 of the human protein is completely conserved in the TACSTD2 and related TACSTD1 proteins of all species thus far sequenced (Table 4 ). Furthermore, in various proteins containing a thyroglobulin type 1A domain, the corresponding position is always phenylalanine or tyrosine ( Table 5 ). Position 114 is close to the highly conserved QC and CWCV motifs of the domain (Tables  4, 5 , and Ref. 34 ). Creation of an additional cysteine residue at this position by mutation most likely affects the three disulfide bonds that normally occur in all thyroglobulin type 1A domains ( Fig. 3 and Ref. 34) .
E227K, which also has not been previously reported, was observed in 10 of the 13 Iranian patients with GDLD, whereas the causative nucleotide substitution was not seen in the 100 control individuals screened. Affected and nonaffected family members were available from five of the pedigrees carrying the variation. A representative pedigree is shown in Figure 4 . In this and all other pedigrees, affected individuals carried the variation in the homozygous state, and nonaffected individuals carried one or two copies of the wild-type nucleotide (Fig. 4) . Glutamic acid at position 227 is completely conserved in TACSTD2 and related proteins ( Table 4 ). The variation identified results in a negatively charged amino acid to be substituted by a positively charged amino acid. These findings strongly suggest that the variation causes GDLD. E227K is positioned in the region between the TY and TM domains of TACSTD2.
Variations c.Ϫ54AϾC in the 5Ј noncoding region, c.441GϾC causing E147D, and c.648CϾA causing D216E are thought not to be associated with GDLD. The altered nucleotides at c.Ϫ54 (C) and c.441 (C) were observed in 8.6% and 16.5%, respectively, of the chromosomes of the 100 healthy control individuals. The relatively high frequency of the variant nucleotides (C at both positions) suggests they are unlikely to cause to the disease. The altered nucleotide at c.648 (A) was not found in any of the Iranian control individuals, but has been reported in the HapMap site (http://www.hapmap.org/cgiperl/gbrowse/hapmap_B35/; rs 232835; Provided by the International HapMap Project, a worldwide consortium of scientists) at frequencies of 0.058, 0.080, 0.131, and 0.427 among European, Chinese, Japanese, and African individuals, respectively. It was also reported as a common polymorphism among the control cohort of a study on GDLD in the Japanese population. 23 It is thus assumed that the variation was not observed among the Iranian control subjects because it is very rare. E174D and D216E both result in the substitution of one negatively charged amino acid for another at nonconserved positions of TACSTD2 (not shown). At position 216 precisely, glutamic acid is found in many TACSTD2-related proteins.
The three variant positions c.Ϫ54AϾC, c.441GϾC, and c.648CϾA, thought not to be associated with GDLD, were * Reference sequences used were NT032977, NM002353, and NP002344.1. Bold: variations thought to cause GDLD. † All patients carried the variations in the homozygous state. ‡ The variations were assessed by RFLP in 100 control individuals. The restriction enzyme used for each variation is indicated in parenthesis. For analysis of variation c.341TϾG, a 175-bp fragment was amplified using M1S1-Fm (5Ј-CCACGCTGACCTCCAAGTGTC-3Ј) and M1S1-Rm (5Ј-CACACCGACGTCTGGTTGTAC-3Ј). A nucleotide variation (shown in bold) was introduced into M1S1-Rm, so as to eliminate a cleavage site and facilitate interpretation of electrophoretic patterns. used to define intragenic haplotypes. Three haplotypes, -AGC-, -CGC-, and -ACC-were identified among the control subjects, and the most frequent of these was -AGC-(71.6%). Three of our putative disease-causing variations, C66X, F114C, and L186P, were found on this haplotype background. All alleles carrying the E227K mutation common among the Iranian patients were associated with a fourth haplotype -CCA-, not found among the control subjects.
DISCUSSION
Four disease-associated mutations in TACSTD2, C66X, F114C, L186P, and E227K, were identified among the 13 Iranian GDLD pedigrees studied. Three of the mutations are novel. E227K was common among the Iranian patients, having been observed in probands of 10 of the pedigrees. All E227K mutated alleles identified were associated with the haplotype -CCA-, and this haplotype was not observed among the chromosomes of 100 Iranian control individuals. Furthermore, at least two mutation and/or recombination events between the haplotypes found among the control subjects would be required to create the -CCA-haplotype. The linkage of all observed E227K mutated alleles with the same haplotype and the rarity of that haplotype among Iranians suggest that E227K is a founder mutation in this population. In addition, the E227K mutation originally either occurred on a very rare haplotype background or was introduced into the population. The other three muta-tions of the Iranian patients were all associated with a haplotype (-AGC-) common among the Iranian control cohort. However, as the haplotype is expected to be common worldwide based on allele frequencies available at the HapMap site, the origin of the mutations cannot be assessed (not shown). These mutations were rare and, therefore, are expected to have been introduced more recently than E227K. The c.653delA mutation recently reported in a GDLD patient from nearby Turkey was not found among the Iranian patients. 21 Mutations affecting initiation of protein synthesis or those creating early stop codons and frame shifts during translation are generally expected to have global detrimental effects on protein function. However, those causing amino acid alterations may be more informative with regard to the biochemical reason for development of a disease phenotype. With regards to GDLD, 8 of the 21 reported putative disease-causing mutations produce amino acid alterations (including mutations presented in this study and excluding M1R which affects initiation of protein synthesis). Four of these (C108R, F114C, Q118E, and C119S) change amino acids within the TY domain of TACSTD2 and the remaining four (Y184C, L186P, V194E, and E227K) change amino acids within a region between the TY and TM domains, signifying the importance of these regions in relation to TACSTD2 function. The TY domain is constituted by only 76 of the 323 amino acids of TACSTD2 (residues 70-145; http:// ca.expasy.org/uniprot/P09758). The function of the region between the TY and TM domains is unknown, but the mutations 
GD in the TY domain may affect its role as a protease inhibitor and thus affect amyloid deposition. 35, 36 Mutation C66X causes very early protein truncation during protein synthesis. This nonsense codon may also result in reduced levels of mRNA. 37 GDLD could be due to the absence of functional TASCTD2 and/or effects of the truncated protein.
It is interesting that the patient carrying this mutation showed initial symptoms of disease only at the age of 20, later than all the other patients studied. Different individuals within the same or different pedigrees carrying the same E227K mutation presented various phenotypic features. For example, age at onset in different individuals carrying the E227K mutation ranged from 4 months to 7 years within the same pedigree (pedigree 100-4) and from 4 months to 18 years in different pedigrees ( Table 2 ). Whereas amyloid deposition initially oc-curred centrally in the cornea of most of the E227K carrying patients, deposition was paracentral in the eyes of two patients (pedigrees 100-7 and 100-8; Table 2 , Fig. 2A ). These observations suggest that factors in addition to mutations in TACSTD2 may affect the phenotypic features of patients with GDLD.
